The raised guidance reflects accelerating momentum in the Plasma/Apheresis segment, which posted 17.7% organic growth. Watch for continued execution on the CSL relationship and margin trajectory, as adjusted operating margin guidance was narrowed to the lower end of prior expectations.
Price Chart
Executive Summary
Haemonetics reported Q2 fiscal 2027 revenue of $357.8M, up 9.3% YoY, and adjusted EPS of $1.35, beating the $1.29 consensus. The company raised its full-year reported revenue guidance to 8-11% (from 5-8%) and organic revenue guidance to 6-9% (from 4-7%), driven by strong Apheresis growth (+13.6% organic) and margin expansion.
Key Financial Metrics
Key Facts
- Q2 FY2027 revenue $357.8M, up 9.3% YoY, above $345.1M consensus
- Adjusted EPS $1.35, up 6.3% YoY, above $1.29 consensus (beat 4.7%)
- GAAP EPS $1.00 vs $0.81 YoY
- Organic revenue growth 10.0% (Apheresis +13.6%, MedSurg +5.5%)
- Raised FY2027 reported revenue guidance to 8-11% from 5-8%
- Raised organic revenue guidance to 6-9% from 4-7%
- Adjusted operating margin guidance narrowed to 0-50 bps expansion from 50-100 bps
- Free cash flow $103.8M in Q2, up 17.0% YoY
- Cash from operations $128.1M, up 15.1% YoY
- Share repurchases of $75M year-to-date
Financial Impact
Revenue beat consensus by $12.7M (3.7%); adjusted EPS beat by $0.06 (4.7%); guidance raised by ~300 bps on reported revenue and ~200 bps on organic revenue
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Apheresis | $204.8M | +12.6% |
| MedSurg | $153.0M | +5.1% |
Risk Factors
- Adjusted operating margin guidance narrowed to 0-50 bps expansion from 50-100 bps, suggesting some margin pressure from investments
- Interest expense increased 70.1% YoY to $12.3M due to higher debt levels
- Effective tax rate rose to 26.3% from 24.6% due to valuation allowances on deferred tax assets from acquisitions
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000313143-26-000150 |
| Document: hae-20261105.htm | 0000313143-26-000150 |
| Document: 0000313143-26-000150-index-headers.html | 0000313143-26-000150 |
| Document: 0000313143-26-000150-index.html | 0000313143-26-000150 |
| Document: 0000313143-26-000150.txt | 0000313143-26-000150 |
| 8-K Data (Synthetic) | 0000313143-26-000150 |
Track record
14 reports on HAE
2 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +2.44% at T+5 after the Oct 20, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $122.71 Now $121.34 −1.12% settles Nov 19
- Nov 5, 202611d ago 8-K Bullish 6/10 Viewing No price data
- Nov 5, 202611d ago Press Release Bullish 5/10 Entry $124.11 to $122.71 Now $121.34 −2.23% ▼ −1.13% −4.42% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bullish 4/10 Entry $117.11 to $119.97 Now $121.34 +3.61% ▲ +2.44% +2.89% vs SPY
- Oct 19, 202628d ago Press Release Bullish 7/10 Entry $118.21 to $119.97 Now $121.34 +2.65% ▲ +1.49% +1.41% vs SPY
- Oct 12, 20265w ago Institutional Cluster Bullish 4/10 Entry $122.06 to $118.73 Now $121.34 −0.59% ▼ −2.73% −1.23% vs SPY
- Oct 8, 20265w ago 8-K Neutral 4/10 Entry $119.47 to $121.29 Now $121.34 +1.57% ▲ +1.52% +1.80% vs SPY
- Sep 30, 20266w ago Press Release Neutral 1/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Sep 30, 20266w ago Court Ruling Neutral 3/10 Entry $104.37 to $119.47 Now $121.34 +16.26% ▲ +14.47% +13.17% vs SPY
- Aug 18, 202612w ago 8-K Neutral 3/10 Entry $104.65 to $108.32 Now $121.34 +15.95% ▲ +3.51% +3.71% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers